Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the expression of target genes. Therefore, the efficacy of the targeted therapies for canine HCC remains unclear.
In HCC, the prognosis is generally good when complete surgical resection is possible. Unresectable nodular and diffuse HCC have a poor prognosis and limited nonsurgical treatment options. In humans, systemic therapies including targeted therapies are indicated when curative treatment is difficult. Targeted therapy includes the use of conventional molecular targeted agents, hormonal agents, immune checkpoint inhibitors, and targeted cytotoxic therapy. Despite the high anticancer activity of the targeted therapy, the agents can only be applied to patients with targeted gene mutations or abnormalities. For these targeted genes, the therapeutic agents exert antitumor effects by inhibiting cell proliferation, metastasis, and angiogenesis, reversing multidrug resistance, and inducing apoptosis. In canine unresectable HCC, sorafenib is used as targeted therapy. However, there are limited reports on the expression status of the target gene. Moreover, up regulation of PDGFB is reported in canine HCC as a potential gene for targeted therapy. However, the application of targeted therapy in canine HCC is not clear. Therefore, in this study, we assessed the expression of target genes in canine HCC based on their expression in human tumors.
###
About OMU
Established in Osaka as one of the largest public universities in Japan, Osaka Metropolitan University is committed to shaping the future of society through “Convergence of Knowledge” and the promotion of world-class research. For more research news, visit https://www.omu.ac.jp/en/ and follow us on social media: X , Facebook , Instagram , LinkedIn .
BMC Research Notes
Candidate genes in canine hepatocellular carcinoma for molecular targeted therapy
2-Dec-2024